Share This Page
Suppliers and packagers for generic pharmaceutical drug: afamelanotide
✉ Email this page to a colleague
afamelanotide
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Clivunel Inc | SCENESSE | afamelanotide | IMPLANT;SUBCUTANEOUS | 210797 | NDA | CLINUVEL INC. | 73372-0116-1 | 1 VIAL, GLASS in 1 CARTON (73372-0116-1) / 1 mg in 1 VIAL, GLASS | 2019-12-31 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers and packagers for generic pharmaceutical drug: afamelanotide
Afamelanotide Suppliers: Who Manufactures, Supplies, and Licenses the Melanocortin Therapy for Erythropoietic Protoporphyria (EPP)
Executive summary: Afamelanotide’s supply chain is centered on one commercial product approval and limited advanced development tooling. The drug is marketed in the US as Scenesse (afamelanotide). Core suppliers are typically split across (1) commercial drug substance and drug product manufacturing, (2) clinical trial material manufacturing, and (3) packaging, labeling, and distribution. Public, dossier-level granularity for each step is often controlled contractually and does not always map cleanly to publicly listed “supplier” names. Below is the supplier landscape that can be substantiated from public regulatory and product information and that is actionable for vendor qualification, licensing due diligence, and litigation or supply-risk analysis.
Who supplies afamelanotide (Scenesse) to pharma and health systems?
Answer (commercial): Afamelanotide is supplied through the marketing/distribution channel for Scenesse in approved markets. The direct “supplier” to end users is the marketing authorization holder and commercial distributor for each jurisdiction, while manufacturing suppliers are the licensed manufacturers of drug substance (API) and finished drug product (drug product).
Commercial product anchor: Scenesse
- Brand: Scenesse
- Active ingredient: afamelanotide
- Indication: reduction of phototoxicity in adults with erythropoietic protoporphyria (EPP)
- Role in supplier mapping: Scenesse is the reference point for supplier identification because the manufacturing sites and quality system are tied to regulatory filings for the marketed product.
Supplier categories you should map in diligence
- Drug substance (API) manufacturer
- Drug product manufacturer (finished dosage form)
- Fill-finish and sterile handling supplier (if applicable to product form)
- Quality control release labs (internal or outsourced)
- Primary/secondary packaging and labeling suppliers
- Wholesale distribution partners in each country
What manufacturers produce afamelanotide drug substance and drug product?
Answer: Afamelanotide manufacturing is split between licensed manufacturing sites that appear in regulatory submissions and product listings for Scenesse. In practice, the most defensible supplier identification comes from:
- FDA and EMA product regulatory documents (when accessible via public summaries)
- National competent authority databases (where they publish manufacturing site data)
- Company quality and CMC disclosures in public regulatory artifacts
Drug product vs drug substance supplier split
For afamelanotide, supplier identification should be treated as two separate procurement streams:
- API supply for consistent peptide synthesis, purification, and analytical release
- Finished product supply for the implant formulation, aseptic controls (if applicable to the product manufacturing route), and device-like handling requirements
How to structure a qualification package
- Supplier manufacturing site GMP scope for peptide APIs
- Sterility assurance or microbiological controls applicable to the final form
- Change control history (site transfers, process validation updates)
- Analytical method transfer capability for stability and lot release
- Cold-chain and temperature excursion history for peptide products
What is the Orange Book status of afamelanotide (Scenesse) and how does it affect supplier access?
Answer: Afamelanotide is protected by a patent estate and managed through branded supply rather than a typical generic-to-Orange-Book dynamic. The practical effect on suppliers is that third-party API or contract manufacturing for an unapproved generic is constrained by IP and regulatory pathway risk.
How exclusivity and patents shape supplier choices
- Branded supply chain is stable because API and finished product manufacturing are locked to approved CMC dossiers and validated methods.
- Generic or authorized copy production generally requires:
- regulatory pathway support
- IP clearance (freedom-to-operate for formulation, method, and device-related claims, if any)
- bridging strategy to satisfy regulators on comparability of the implant and peptide release characteristics
Which contract manufacturing organizations (CMOs) support afamelanotide supply?
Answer: The specific CMO names that manufacture afamelanotide’s commercial product depend on the Scenesse regulatory dossier manufacturing site listings and any publicly documented outsourcing arrangements. In most branded peptide implant products, CMO involvement is common for:
- peptide synthesis steps and purification outsourcing
- analytical release outsourcing (bioanalytical, stability testing)
- packaging and labeling
Actionable diligence approach (procurement-ready):
- Identify the GMP sites listed for Scenesse drug substance and drug product
- Check those sites’ GMP inspection history
- Validate whether the site is the actual manufacturer or an oversight distributor with sub-contracting
- Confirm ability to support:
- annual product lot supply volume forecasts
- change control timelines for method revalidation
- stability program maintenance and comparability documentation
What do afamelanotide distribution and wholesale supply networks look like by geography?
Answer: Distribution is handled through market authorization holder channels and local wholesale distributors depending on country rules. The supplier risk pattern for afamelanotide is typically:
- concentrated manufacturing geography for peptide/implant production
- country-specific distribution agreements for prescribing centers and hospitals
Key supplier-risk questions to run internally
- Single-source manufacturing of API and finished product
- Limited second-source qualified packaging/labeling vendors
- Lack of inventory buffering for specialty implant products
- Dependence on cold-chain logistics or temperature control requirements during distribution
What supplier requirements apply to afamelanotide (peptide implant) CMC qualification?
Answer: Afamelanotide suppliers must satisfy peptide manufacturing controls plus finished product controls for the approved implant presentation.
CMC controls that drive vendor qualification
- Peptide identity and impurity profile
- specified mass confirmation (e.g., LC-MS where used)
- impurity monitoring aligned with stability and specification
- Process reproducibility
- validated synthesis and purification steps
- batch record review and deviations handling
- Stability program and shelf-life support
- long-term stability
- stress conditions
- packaging component compatibility
- Documentation readiness
- DMF/ASMF alignment for API if applicable
- CoA, CoC, and full batch traceability
- analytical method validation records
How do supplier constraints differ for afamelanotide clinical vs commercial supply?
Answer: Clinical supply tends to have more supplier flexibility and smaller scale, while commercial supply needs:
- validated batch processes
- validated analytical methods for release and stability
- contractual throughput commitments
Commercial scale considerations
- robust supply continuity and lot release cadence
- site-specific validated sterility assurance, if the product form needs it
- packaging line validation for implant handling requirements
What supplier risks exist if afamelanotide demand spikes or supply is disrupted?
Answer: The principal risks for specialty peptide/implant products are:
- limited number of qualified peptide and implant suppliers
- long lead times for peptide synthesis materials and analytical reagents
- dependency on site-specific validated processes that take time to transfer
Mitigation mechanisms that procurement teams typically implement
- dual-source contracts for non-API critical materials (where possible)
- inventory safety stock buffers at wholesalers and major centers
- pre-qualification of secondary packaging/labeling vendors
- validated tech transfer plan with defined timelines
Which companies are afamelanotide “suppliers” in the practical sense (marketing authorization and distribution)?
Answer: In practical procurement and tendering, the relevant “supplier” is the commercial entity responsible for product availability under local rules. For afamelanotide, that is tied to Scenesse commercialization.
Supplier mapping framework
When identifying a “supplier” for contracting or tendering, split:
- Commercial supply entity (product availability, pricing, tender fulfillment)
- Manufacturing entity (GMP site for drug substance and drug product)
- Logistics/distribution entity (wholesaler, 3PL, import/distribution)
Key Takeaways
- Afamelanotide supply is organized around Scenesse commercialization, with manufacturing split across drug substance and finished drug product GMP sites.
- “Supplier” can mean three different functions: marketing/distribution, API/drug product manufacturing, and packaging and logistics. Vendor qualification should map to the function you need.
- Procurement and supply risk are dominated by single-site peptide/implant manufacturing constraints, long CMC lead times, and contract-controlled technology transfer.
FAQs
1) Who makes afamelanotide implants for Scenesse?
The manufacturer is the GMP site(s) listed in Scenesse’s regulatory manufacturing disclosures for drug substance and drug product; contract manufacturing arrangements are typically reflected in those site disclosures.
2) Can you source afamelanotide API from alternate suppliers?
Alternate API sourcing requires freedom-to-operate and dossier bridging to approved specifications; commercial substitution is constrained by IP and regulatory approval dependencies.
3) What are typical qualification requirements for afamelanotide peptide suppliers?
Peptide impurity profiling, batch reproducibility, stability program alignment, and validated analytical release capability.
4) What supply disruptions are most likely for peptide implant drugs like afamelanotide?
Limited qualified manufacturing sites, long peptide synthesis lead times, and packaging/handling constraints for the implant presentation.
5) How do you reduce risk of supply shortage for Scenesse-like products?
Use inventory buffers, pre-qualify backup packaging/distribution partners, and build tech transfer and change control plans for second manufacturing capability where feasible.
References (APA)
- FDA. (n.d.). Drug trials snapshots and labeling information for Scenesse (afamelanotide). U.S. Food and Drug Administration.
- EMA. (n.d.). EPAR and product information for Scenesse (afamelanotide). European Medicines Agency.
- United States Patent and Trademark Office (USPTO). (n.d.). Patent records for afamelanotide and Scenesse. USPTO.
More… ↓
